SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-005977
Filing Date
2021-02-02
Accepted
2021-02-02 08:15:19
Documents
3
Period of Report
2021-01-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea134387-8k_protaratherap.htm 8-K 23877
2 PRESS RELEASE, DATED FEBRUARY 2, 2021 ea134387ex99-1_protaratherap.htm EX-99.1 10289
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8197
  Complete submission text file 0001213900-21-005977.txt   47078
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 21579093
SIC: 2836 Biological Products, (No Diagnostic Substances)